Sugi Predict

Sugi Predict / Compounds / SCHEMBL5895323

SCHEMBL5895323

SCHEMBL5895323

CC(C)(C)OC(=O)N1CCC2(CCC2=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ DDB1 Q16531 1/20 0.44
▸ CRBN Q96SW2 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.44
▸ ALOX15 P16050 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.40
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20521260 0.91 USP30 (0.50) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL31566493 0.91 USP30 (0.50) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL31566998 0.91 USP30 (0.50) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL4774216 0.91 USP2 (0.45) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL16914278 0.89 USP2 (0.44) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL24088990 0.88 HPGD (0.43) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL22958850 0.88 HPGD (0.43) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL736466 0.85 ESR2 (0.47) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL20601939 0.85 USP30 (0.42) USP2SMN1; SMN2DDB1CRBNUSP30
SCHEMBL24089120 0.83 USP2 (0.50) USP2SMN1; SMN2DDB1CRBNUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 — — EP disclosed
EP-4587435-A1 MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS Cullgen (Shanghai), Inc. (CN) 2025-07-23 — — EP disclosed
US-20250115571-A1 OXOPIPERAZINE DERIVATIVES Inthera Bioscience AG (CH) 2025-04-10 — — US disclosed
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
EP-3645533-B1 TDO2 AND IDO1 INHIBITORS GENENTECH INC (US) 2025-03-26 — — EP disclosed
US-12209098-B2 N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG (CH) 2025-01-28 — — US disclosed
CN-113302184-B 1,3, 4-Oxadiazolinone compounds and medicaments 日本新药株式会社 2024-11-22 — — CN disclosed
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 — — EP disclosed
US-20240217983-A1 GPR119 AGONISTS KALLYOPE, INC. 2024-07-04 — — US disclosed
US-9938295-B2 — — 2018-04-10 — — US disclosed
WO-2017102677-A1 2,4,6,7-TETRASUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-06-22 — — WO disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed
US-20170015680-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2017-01-19 — — US disclosed
US-20170015680-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2017-01-19 — — US disclosed
US-20170015680-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2017-01-19 — — US disclosed
WO-2016203404-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2016-12-22 — — WO disclosed
WO-2015107495-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2015-07-23 — — WO disclosed
US-7091211-B2 Cyclopentyl modulators of chemokine receptor activity MERCK & CO., INC. (US) 2006-08-15 — — US disclosed
US-20050070609-A1 Cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2005-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115571-A1 OXOPIPERAZINE DERIVATIVES CYP3A5, AQP1, AVPR2 USP2 3518/4885SMN1; SMN2 1963/4885DDB1 4086/4885
US-20240217983-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR USP2 3319/4885SMN1; SMN2 1661/4885DDB1 4220/4885
US-20170015680-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 PTPN5, PTPN1, PTPN7 USP2 1924/4885SMN1; SMN2 2598/4885DDB1 1556/4885
US-12209098-B2 N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 PTPN5, PTPN1, PTPN7 USP2 1924/4885SMN1; SMN2 2598/4885DDB1 1556/4885
US-20050070609-A1 Cyclopentyl modulators of chemokine receptor activity CCR5, CXCR1, ACKR3 USP2 4590/4885SMN1; SMN2 4725/4885DDB1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.